<DOC>
	<DOC>NCT02253459</DOC>
	<brief_summary>The purpose of this study is to determine whether UTD1 Injection in combination with capecitabine is effective in the treatment of advanced metastatic breast cancer using capecitabine as a control.</brief_summary>
	<brief_title>Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1. Histologically and/or cytologically diagnosed patients with advanced, metastatic breast cancer,or lacking standard therapy or being failed to or recurrent after standard therapy; 2. Patients who have previously treated with ≤4 chemotherapeutic regimes; 3. Patients who have previously treated with an anthracyclin antibiotics and a taxane; 4. Age 18 70 years old, ECOG performance status of 02; Life expectancy of 3 months or more; 5. Patients with at least 1 measurable target lesion determined by CT within 2 weeks prior to enrollment; 6. Neuropathy ＜CTC2 degree （NCI CTC4.03）within 4 weeks prior to enrollment; 7. Basically normal results from routine blood test within 1 week prior to enrollment; 8. Basically normal liver and renal functions within 1 week prior to enrollment; 9. No abnormal function for major internal organs, no heart diseases. 1. Received chemotherapy, radiotherapy, therapies with hormones or molecularly targeted drugs 4 weeks prior to enrollment, or received other chemotherapies while participating in this trial; 2. Patients with documented hypersensitivity to Cremophor EL, or patients with previous taxane treatment related SAE; 3. Patients of pregnancy or breast feeding; 4. Patients with previous standard capecitabine treatment ineffective, or patients received standard capecitabine treatment effective, but with less than 6 months of capecitabine clearance period; 5. Patients with uncontrolled brain metastasis or bone metastasis, which plan for recent surgery or local radiotherapy, or other emergency treatment; 6. Patients combined with severe and /or uncontrolled medical conditions, including severe cardiovascular disease, uncontrolled diabetes and high blood pressure, severe infection, severe gastrointestinal ulceration, and patients with incontrollable psychiatric history; 7. Patients with poor compliance; 8. Patients not fitted for this study determined by the investigators.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>